PAH’s Two Main Players Edging Toward Head-To-Head Competition
Although Pfizer Inc. and Gilead Sciences can be found at its margins, the pulmonary arterial hypertension space largely is a two-company competition. Currently, the two main players – United Therapeutics Corp. and Switzerland's Actelion Ltd. – have staked out a competitive advantage in a different portion of the space, but they are about to compete directly.
You may also be interested in...
Impressive Phase III trial data on Actelion’s macitentan and Bayer’s riociguat generated big noises at the annual meeting of the American College of Chest Physicians in Atlanta and should support regulatory filings for the two therapies.
The Maryland-based biotech has been expanding on its lead product line with new formulations and backing it up with strong IP.
The company tells skeptical analysts it will pursue a limited monotherapy label based on a single positive Phase III study in the wake of a second combination trial failure.